Weibo Luo, Ph.D. - Faculty Profile

Biography

Dr. Weibo Luo is currently an Associate Professor of Pathology and Paharmacology. Dr. Luo received his Ph.D summa cum laude from the University of Magdeburg in Germany and completed his postdoctoral fellowship and instructorship at the Johns Hopkins University School of Medicine before joining UT Southwestern.

Dr. Luo studies epigenetic and metabolic alterations through crosstalk with hypoxia in cancer development with the goal of identifiying vulnerability to treat human cancers.

Research Interest

Drug resistance
Epigenetics
Hypoxia/Hypoxia-inducible factor
Immunotherapy
Metabolism
Tumor initiation, growth, and metastasis

Publications

Featured Publications

Tumoral RCOR2 promotes tumor development through dual epigenetic regulation of tumor plasticity and immunogenicity.: Bao L, Zhu M, Luo M, Kumar A, Peng Y, Xing C, Wang Y, Luo W, J Clin Invest 2025 Jul
ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27.: Wang Y, Wang Y, Bao L, Vale G, McDonald JG, Fang Y, Peng Y, Kumar A, Xing C, Brasó-Maristany F, Prat A, Arteaga CL, Wang Y, Luo W, Nat Commun 2025 Apr 16 1 3908
ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.: Luo M, Bao L, Xue Y, Zhu M, Kumar A, Xing C, Wang JE, Wang Y, Luo W, J Clin Invest 2024 Jan 134 6
SAP30 promotes breast tumor progression by bridging the transcriptional corepressor SIN3 complex and MLL1.: Bao L, Kumar A, Zhu M, Peng Y, Xing C, Wang JE, Wang Y, Luo W, J Clin Invest 2023 Sep 133 17
ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells.: Luo M, Bao L, Chen Y, Xue Y, Wang Y, Zhang B, Wang C, Corley CD, McDonald JG, Kumar A, Xing C, Fang Y, Nelson ER, Wang JE, Wang Y, Luo W, Sci Adv 2022 07 8 28 eabn5295
Targeting BCAT1 combined with a-ketoglutarate triggers metabolic synthetic lethality in glioblastoma.: Zhang B, Peng H, Zhou M, Bao L, Wang C, Cai F, Zhang H, Wang JE, Niu Y, Chen Y, Wang Y, Hatanpaa K, Copland JA, DeBerardinis RJ, Wang Y, Luo W, Cancer Res 2022 May
ZMYND8 expression in breast cancer cells blocks T-lymphocyte surveillance to promote tumor growth.: Wang Y, Luo M, Chen Y, Wang Y, Zhang B, Ren Z, Bao L, Wang Y, Wang JE, Fu YX, Luo W, Wang Y, Cancer Res 2020 Nov
HIF-2-induced long non-coding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis.: Niu Y, Bao L, Chen Y, Wang C, Luo M, Zhang B, Zhou M, Wang JE, Fang YV, Kumar A, Xing C, Wang Y, Luo W, Cancer Res. 2020 Jan
Methylation of hypoxia-inducible factor (HIF)-1a by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration.: Bao L, Chen Y, Lai HT, Wu SY, Wang JE, Hatanpaa KJ, Raisanen JM, Fontenot M, Lega B, Chiang CM, Semenza GL, Wang Y, Luo W Nucleic Acids Res. 2018 May
ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.: Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, Kumar A, Wang JE, Wang C, Zou X, Xing C, Wang Y, Luo W J. Clin. Invest. 2018 Apr

Honors & Awards

ACS Research Scholar
(2021)
Mary Kay Foundation Research Award
(2019)
Susan G. Komen Career Catalyst Research Award
(2016)
Welch Foundation Research Award
(2016)
American Cancer Society (ACS-IRG) New Investigator Awards in Cancer Research
(2015)
CPRIT Scholar in Cancer Research
Cancer Prevention Research Institute of Texas (2014)
AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Award
American Association for Cancer Research (2013)
NIH Pathway to Independence Award
National Cancer Institute (2013)
Albert L. Lehninger Postdoctoral Research Award
The Johns Hopkins University School of Medicine (2012)
FARMS Postdoctoral Fellowship
Dr. Richard and Mavis Fowler Foundation for Advanced Research in the Medical Sciences, Inc (2011)
PhD summa cum laude
University of Magdeburg, Germany (2007)

Professional Associations/Affiliations

American Association for Cancer Research (2011)